DE69712731T2 - Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten - Google Patents
Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patientenInfo
- Publication number
- DE69712731T2 DE69712731T2 DE69712731T DE69712731T DE69712731T2 DE 69712731 T2 DE69712731 T2 DE 69712731T2 DE 69712731 T DE69712731 T DE 69712731T DE 69712731 T DE69712731 T DE 69712731T DE 69712731 T2 DE69712731 T2 DE 69712731T2
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- chimeric
- sensitivity
- inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96200175 | 1996-01-26 | ||
PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69712731D1 DE69712731D1 (de) | 2002-06-27 |
DE69712731T2 true DE69712731T2 (de) | 2003-02-06 |
Family
ID=8223611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69712731T Expired - Lifetime DE69712731T2 (de) | 1996-01-26 | 1997-01-24 | Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten |
Country Status (21)
Country | Link |
---|---|
US (3) | US6221578B1 (de) |
EP (1) | EP0877937B1 (de) |
KR (1) | KR100495690B1 (de) |
CN (2) | CN1209875A (de) |
AT (1) | ATE217971T1 (de) |
AU (1) | AU717755B2 (de) |
BG (1) | BG102710A (de) |
BR (1) | BR9707204A (de) |
CZ (1) | CZ292899B6 (de) |
DE (1) | DE69712731T2 (de) |
ES (1) | ES2177922T3 (de) |
HU (1) | HU226203B1 (de) |
IL (1) | IL125442A (de) |
IS (1) | IS4799A (de) |
NO (1) | NO321329B1 (de) |
NZ (1) | NZ325912A (de) |
PL (1) | PL186473B1 (de) |
SK (1) | SK283878B6 (de) |
TR (1) | TR199801443T2 (de) |
WO (1) | WO1997027480A1 (de) |
ZA (1) | ZA97669B (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2140929C (en) | 1992-08-25 | 2006-09-12 | Michael L. Vazquez | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
CA2298102A1 (en) * | 1997-07-30 | 1999-02-11 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
CN1204266C (zh) * | 1998-05-26 | 2005-06-01 | 病毒科学公司 | 监控非核苷类逆转录酶抑制剂抗逆转录病毒治疗的途径与方法 |
ATE302287T1 (de) | 1999-05-28 | 2005-09-15 | Virco Nv | Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz |
US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
EP1109019A1 (de) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease |
AU2001233513A1 (en) * | 2000-02-04 | 2001-08-14 | K.U. Leuven Research And Development | Hiv-1 resistance assay |
GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
DE60135366D1 (de) * | 2000-04-18 | 2008-09-25 | Virco Bvba | Methode zur bestimmung der resistenz gegen medikamente |
US6800463B1 (en) | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
AU2001256318B8 (en) * | 2000-04-20 | 2007-03-22 | Virco Bvba | Method for mutation detection in HIV using pol sequencing |
US6582901B2 (en) | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
CN1446265A (zh) * | 2000-06-12 | 2003-10-01 | 病毒科学公司 | 检测抗反转录病毒治疗的方式与方法和在hiv/aids治疗中的指导治疗方案 |
US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
JP2004512032A (ja) | 2000-10-20 | 2004-04-22 | ビルコ・ビーブイビーエイ | 表現型薬物耐性と相互に関連付けられるhiv−1逆転写酵素中の新たな突然変異の特徴 |
US7292944B2 (en) | 2000-10-20 | 2007-11-06 | Virco Bvba | Establishment of biological cut-off values for predicting resistance to therapy |
US7306901B2 (en) | 2001-08-08 | 2007-12-11 | Tibotec Pharmaceuticals, Ltd. | Methods and means for assessing HIV envelope inhibitor therapy |
US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
JP2005513420A (ja) | 2001-11-08 | 2005-05-12 | テイボテク・フアーマシユーチカルズ・リミテツド | 治療薬をモニタリングするためのプロテアーゼアッセイ |
ATE397669T1 (de) | 2002-07-01 | 2008-06-15 | Tibotec Pharm Ltd | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase |
DE60327768D1 (de) | 2002-07-01 | 2009-07-09 | Tibotec Pharm Ltd | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
JP5213228B2 (ja) * | 2004-03-02 | 2013-06-19 | ビルコ・ビーブイビーエイ | 臨床的カット−オフ値の推測 |
CN101365808B (zh) | 2005-12-07 | 2012-04-25 | 泰博特克药品有限公司 | 用于评估hiv病毒适应度的方法、质粒载体和引物 |
EP2010680A2 (de) * | 2006-04-14 | 2009-01-07 | Tibotec Pharmaceuticals Ltd. | Verfahren und mittel zur beurteilung von hiv-gag-/proteasehemmer-therapie |
EP2162745A1 (de) | 2007-05-25 | 2010-03-17 | Tibotec Pharmaceuticals | Neues mutationsprofil bei einer hiv1-gag-spaltstelle in korrelation mit phänotypischer arzneistoffresistenz |
EP2342363B1 (de) * | 2008-10-06 | 2015-06-10 | Janssen Diagnostics BVBA | Verfahren zur bestimmung von arzneistoffresistenz-mutationen in einem der nicht-strukturprotein-bereiche ns3 bis ns5b von hepatitis c-virus (hcv) für genotypen 1 bis 6 |
US20120064514A1 (en) * | 2009-05-12 | 2012-03-15 | Virco Bvba | Hiv-1-c resistance monitoring |
CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875396A (en) * | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
IL94482A (en) | 1989-05-25 | 2003-09-17 | Univ Duke | Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
ES2113546T3 (es) | 1992-07-06 | 1998-05-01 | Harvard College | Metodos y estuches de diagnostico para determinar la toxicidad de un compuesto utilizando promotores de estres bacterianos fusionados con genes reporteros. |
US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
US6063562A (en) * | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
WO1997012220A2 (en) | 1995-09-15 | 1997-04-03 | Samir Chachoua | Method for the identification and therapeutic use of disease-associated organisms, elements and forces |
US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
ES2175355T3 (es) | 1996-01-29 | 2002-11-16 | Virologic Inc | Composiciones y metodos para determinar la susceptibilidad y la resistencia a farmacos antivirales y rastreo de farmacos antivirales. |
US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
DE69837118T2 (de) | 1997-04-07 | 2007-12-27 | Fisher Biolmage Aps | Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA |
WO1998046796A1 (en) | 1997-04-11 | 1998-10-22 | The Regents Of The University Of California | A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways |
WO1998059074A1 (en) | 1997-06-23 | 1998-12-30 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 EP EP97900712A patent/EP0877937B1/de not_active Expired - Lifetime
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/xx unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69712731T2 (de) | Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten | |
Konigsberg | Migration models of prehistoric postmarital residence | |
Martin | Nucleic acid chaperone properties of ORF1p from the non-LTR retrotransposon, LINE-1 | |
Reeves et al. | Too much of a good thing: mechanisms of gene action in Down syndrome | |
Moens et al. | Chromosome number of a small protist: accurate determination | |
Hunter et al. | Letting the genome out of the bottle-will we get our wish? | |
Aune et al. | Epigenetic activation and silencing of the gene that encodes IFN-γ | |
Mostowy et al. | The role of recombination for the coevolutionary dynamics of HIV and the immune response | |
McLachlan et al. | Functional characterization of oculodentodigital dysplasia-associated Cx43 mutants | |
Elsner et al. | Absence of cGAS-mediated type I IFN responses in HIV-1–infected T cells | |
Chatterjee et al. | Serial number tagging reveals a prominent sequence preference of retrotransposon integration | |
White et al. | Transcriptional modulation of human endogenous retroviruses in primary CD4+ T cells following vorinostat treatment | |
Riou et al. | Severe symptomatic primary human cytomegalovirus infection despite effective innate and adaptive immune responses | |
Xue et al. | The functional and evolutionary impacts of human-specific deletions in conserved elements | |
van den Ham et al. | From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation | |
Roy Chowdhury et al. | NK-like CD8+ γδ T cells are expanded in persistent Mycobacterium tuberculosis infection | |
Fitch et al. | Evolutionary rates in proteins: neutral mutations and the molecular clock | |
Berrocal et al. | Unified bursting strategies in ectopic and endogenous even-skipped expression patterns | |
Chen et al. | Methods taught in dental schools for determining the posterior palatal seal region. | |
Dawson et al. | Electrochemical noise--some new developments in corrosion monitoring | |
Indrasamy et al. | Fluctuating asymmetry for specific bristle characters in Notch mutants of Drosophila melanogaster | |
DE60018117D1 (de) | Methodologie um pflanzen und andere organismen mit von der normalen probe abweichenden charakteristiken zu identifizieren | |
Chau et al. | IFN-γ gene expression is controlled by the architectural transcription factor HMGA1 | |
Larson | A reevaluation of the relationship between genome size and genetic variation | |
Zhao et al. | Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |